In fiscal 2020, despite the difficult environment, we will work to improve the profitability of each of our businesses and promote business growth in the healthcare and highly functional materials business fields along with a new growth strategy in the document business. On the financial side, we will strengthen our cash management and maintain financial soundness. Beginning this fiscal year, we have introduced ROIC*1 and CCC*2 as metrics for assessing business divisions for improving ROE*3, and by strengthening management from these standpoints, we will maximize our cash generation capabilities. While working to improve profitability by promoting cost reductions in each business, we will make prioritized capital injections in the necessary domains with respect to capital expenditures and R&D expenses for growth, tying this into the next breakthrough. We will maintain an annual dividend of JPY 95 per share.